DISC-0974
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis; Anemia
Conditions
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Trial Timeline
Jun 6, 2022 → Sep 1, 2026
NCT ID
NCT05320198About DISC-0974
DISC-0974 is a phase 1/2 stage product being developed by Disc Medicine for Myelofibrosis; Anemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05320198. Target conditions include Myelofibrosis; Anemia, Anemia, Myelofibrosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05320198 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Myelofibrosis; Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 41 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 52 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 77 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 23 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 77 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 52 |
| AZD1480 | AstraZeneca | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Peginterferon alfa-2a | Merck | Phase 2 | 52 |
| Bomedemstat | Merck | Phase 1/2 | 41 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 33 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 33 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 41 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 41 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |